Tag Archives: Mesothelioma

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »

WCLC: Bristol Myers’ Opdivo-Yervoy duo slashes mesothelioma death risk by 26%

It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines. Saturday at the World Conference on Lung Cancer’s virtual presidential symposium, Bristol Myers unveiled phase 3 data showing the pair decreased the risk of death among previously untreated mesothelioma patients by 26%, helping them live… Read More »